Jason Liebowitz, MD | Issue: May 2022 |
When Jonathan Kay, MD, attends a medical lecture, he does more than just listen to the speakers or watch their presentations. He typically whips out his pen and draws a caricature of someone in the room. Dr. Kay is a professor of medicine and holds the Timothy S. and Elaine L. Peterson Chair in Rheumatology…
ATLANTA—At the 2019 ACR/ARP Annual Meeting in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find a…
As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…
Although amyloidosis is not a rheumatic disease, rheumatologists may be the first to diagnose this life-threatening condition